These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30916904)

  • 1. [Paradoxical psoriasis induced by anti-TNF - a clinical challenge].
    Nidegger A; Mylonas A; Conrad C
    Rev Med Suisse; 2019 Mar; 15(644):668-671. PubMed ID: 30916904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stricturing and Fistulizing Crohn's Disease Is Associated with Anti-tumor Necrosis Factor-Induced Psoriasis in Patients with Inflammatory Bowel Disease.
    Weizman AV; Sharma R; Afzal NM; Xu W; Walsh S; Stempak JM; Nguyen GC; Croitoru K; Steinhart AH; Silverberg MS
    Dig Dis Sci; 2018 Sep; 63(9):2430-2438. PubMed ID: 29736839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study.
    Pugliese D; Guidi L; Ferraro PM; Marzo M; Felice C; Celleno L; Landi R; Andrisani G; Pizzolante F; De Vitis I; Papa A; Rapaccini GL; Armuzzi A
    Aliment Pharmacol Ther; 2015 Oct; 42(7):880-8. PubMed ID: 26235565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients.
    Peer FC; Miller A; Pavli P; Subramaniam K
    Intern Med J; 2017 Dec; 47(12):1445-1448. PubMed ID: 29224199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis.
    Vasconcellos JB; Pereira DD; Vargas TJ; Levy RA; Pinheiro GD; Cursi ÍB
    An Bras Dermatol; 2016; 91(5 suppl 1):137-139. PubMed ID: 28300922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
    Melo FJ; Magina S
    Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: A Nationwide Cohort Study.
    Guerra I; Pérez-Jeldres T; Iborra M; Algaba A; Monfort D; Calvet X; Chaparro M; Mañosa M; Hinojosa E; Minguez M; Ortiz de Zarate J; Márquez L; Prieto V; García-Sánchez V; Guardiola J; Rodriguez GE; Martín-Arranz MD; García-Tercero I; Sicilia B; Masedo Á; Lorente R; Rivero M; Fernández-Salazar L; Gutiérrez A; Van Domselaar M; López-SanRomán A; Ber Y; García-Sepulcre M; Ramos L; Bermejo F; Gisbert JP;
    Inflamm Bowel Dis; 2016 Apr; 22(4):894-901. PubMed ID: 26933750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis.
    Conrad C; Di Domizio J; Mylonas A; Belkhodja C; Demaria O; Navarini AA; Lapointe AK; French LE; Vernez M; Gilliet M
    Nat Commun; 2018 Jan; 9(1):25. PubMed ID: 29295985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Paradoxical" arthralgia occurring under anti-TNFα treatment for inflammatory bowel disease.
    Sondag M; Verhoeven F; Guillot X; Prati C; Briot C; Vuitton L; Koch S; Wendling D
    Joint Bone Spine; 2018 Jan; 85(1):133-134. PubMed ID: 28115270
    [No Abstract]   [Full Text] [Related]  

  • 12. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
    Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
    Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.
    Collamer AN; Battafarano DF
    Semin Arthritis Rheum; 2010 Dec; 40(3):233-40. PubMed ID: 20580412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical Psoriasis in Children Receiving Anti-TNFα Treatment for Inflammatory/autoimmune Disease.
    Rosenwasser N; Lee D; Sidbury R; Zhao Y
    Paediatr Drugs; 2021 Mar; 23(2):131-141. PubMed ID: 33761130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dermatological Manifestations in Pediatric Patients with Inflammatory Bowel Diseases on Anti-TNF Therapy.
    Sridhar S; Maltz RM; Boyle B; Kim SC
    Inflamm Bowel Dis; 2018 Aug; 24(9):2086-2092. PubMed ID: 29718343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical Psoriasis Induced by Anti-TNFα Treatment: Evaluation of Disease-Specific Clinical and Genetic Markers.
    Bucalo A; Rega F; Zangrilli A; Silvestri V; Valentini V; Scafetta G; Marraffa F; Grassi S; Rogante E; Piccolo A; Cucchiara S; Viola F; Bianchi L; Ottini L; Richetta A
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33114187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series.
    Afzali A; Wheat CL; Hu JK; Olerud JE; Lee SD
    J Crohns Colitis; 2014 Jun; 8(6):480-8. PubMed ID: 24268978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
    Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
    Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.